Gevokizumab
- Generic Name
- Gevokizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1129435-60-4
- Unique Ingredient Identifier
- QX3JU54GYQ
- Background
Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states. It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.
- Associated Conditions
- -
- Associated Therapies
- -
A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- NSABP Foundation Inc
- Registration Number
- NCT05178576
- Locations
- 🇺🇸
UF Health Davis Cancer Pavilion and Shands Med Plaza, Gainesville, Florida, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 167
- Registration Number
- NCT03798626
- Locations
- 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸WA Uni School Of Med, Saint Louis, Missouri, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
- Conditions
- Interventions
- First Posted Date
- 2014-12-29
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 9
- Registration Number
- NCT02326740
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 15
- Registration Number
- NCT02318914
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
- Conditions
- Interventions
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02315417
Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 312
- Registration Number
- NCT02293564
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 4
- Registration Number
- NCT02258867
Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 84
- Registration Number
- NCT01965145
- Locations
- 🇰🇷
Yonsei University Severance Hospital, Seoul, Korea, Republic of
🇬🇧St Thomas' Hospital, London, United Kingdom
The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 10
- Registration Number
- NCT01950312
- Locations
- 🇺🇸
Long Island Jewish Medical Center, Hearing & Speech Center, New Hyde Park, New York, United States
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 91
- Registration Number
- NCT01882491
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.